Ampio Pharmaceuticals Inc. [AMPE] moved up 21.20: Why It’s Important


Ampio Pharmaceuticals Inc. [AMEX: AMPE] stock went on an upward path that rose over 21.20% on Monday, amounting to a one-week price increase of more than 18.87%. The company report on June 2, 2022 that Ampio Pharmaceuticals’ CEO Mike Martino Issues Letter to Stockholders.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.

Over the last 12 months, AMPE stock dropped by -87.64%. The one-year Ampio Pharmaceuticals Inc. stock forecast points to a potential upside of 91.2. The average equity rating for AMPE stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $62.47 million, with 226.08 million shares outstanding and 209.05 million shares in the current float. Compared to the average trading volume of 3.54M shares, AMPE stock reached a trading volume of 9621004 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Ampio Pharmaceuticals Inc. [AMPE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMPE shares is $2.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMPE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Ampio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 19, 2019. While these analysts kept the previous recommendation, Aegis Capital raised their target price from $15 to $16. The new note on the price target was released on March 17, 2014, representing the official price target for Ampio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $11, while Aegis Capital analysts kept a Buy rating on AMPE stock.

The Average True Range (ATR) for Ampio Pharmaceuticals Inc. is set at 0.03 The Price to Book ratio for the last quarter was 2.22, with the Price to Cash per share for the same quarter was set at 0.10.

AMPE Stock Performance Analysis:

Ampio Pharmaceuticals Inc. [AMPE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.87. With this latest performance, AMPE shares gained by 4.22% in over the last four-week period, additionally sinking by -77.54% over the last 6 months – not to mention a drop of -87.64% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMPE stock in for the last two-week period is set at 51.42, with the RSI for the last a single of trading hit 56.34, and the three-weeks RSI is set at 47.42 for Ampio Pharmaceuticals Inc. [AMPE]. The present Moving Average for the last 50 days of trading for this stock 0.2648, while it was recorded at 0.2142 for the last single week of trading, and 0.8135 for the last 200 days.

Insight into Ampio Pharmaceuticals Inc. Fundamentals:

Return on Equity for this stock declined to -76.23, with Return on Assets sitting at -55.35.

Ampio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.40.

Ampio Pharmaceuticals Inc. [AMPE] Insider Position Details

There are presently around $9 million, or 21.80% of AMPE stock, in the hands of institutional investors. The top three institutional holders of AMPE stocks are: BLACKROCK INC. with ownership of 13,996,074, which is approximately 0.44% of the company’s market cap and around 1.50% of the total institutional ownership; VANGUARD GROUP INC, holding 9,307,338 shares of the stock with an approximate value of $1.7 million in AMPE stocks shares; and STATE STREET CORP, currently with $0.63 million in AMPE stock with ownership of nearly 1.973% of the company’s market capitalization.

Positions in Ampio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 31 institutional holders increased their position in Ampio Pharmaceuticals Inc. [AMEX:AMPE] by around 2,755,219 shares. Additionally, 43 investors decreased positions by around 12,845,582 shares, while 66 investors held positions by with 33,408,393 shares. The mentioned changes placed institutional holdings at 49,009,194 shares, according to the latest SEC report filing. AMPE stock had 10 new institutional investments in for a total of 2,242,375 shares, while 11 institutional investors sold positions of 10,019,303 shares during the same period.